PL2376533T3 - Preparat przeciwciała - Google Patents

Preparat przeciwciała

Info

Publication number
PL2376533T3
PL2376533T3 PL09764858.8T PL09764858T PL2376533T3 PL 2376533 T3 PL2376533 T3 PL 2376533T3 PL 09764858 T PL09764858 T PL 09764858T PL 2376533 T3 PL2376533 T3 PL 2376533T3
Authority
PL
Poland
Prior art keywords
antibody formulation
antibody
formulation
Prior art date
Application number
PL09764858.8T
Other languages
English (en)
Polish (pl)
Inventor
Joachim Momm
Hans-Joachim Wallny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40637230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2376533(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of PL2376533T3 publication Critical patent/PL2376533T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL09764858.8T 2008-12-10 2009-12-09 Preparat przeciwciała PL2376533T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08170884A EP2196476A1 (en) 2008-12-10 2008-12-10 Antibody formulation

Publications (1)

Publication Number Publication Date
PL2376533T3 true PL2376533T3 (pl) 2016-09-30

Family

ID=40637230

Family Applications (2)

Application Number Title Priority Date Filing Date
PL09764858.8T PL2376533T3 (pl) 2008-12-10 2009-12-09 Preparat przeciwciała
PL16162699T PL3072906T3 (pl) 2008-12-10 2009-12-09 Preparat przeciwciała

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL16162699T PL3072906T3 (pl) 2008-12-10 2009-12-09 Preparat przeciwciała

Country Status (31)

Country Link
US (3) US20110236398A1 (Direct)
EP (4) EP2196476A1 (Direct)
JP (5) JP6143416B2 (Direct)
KR (2) KR20170044211A (Direct)
CN (3) CN104399076B (Direct)
AU (1) AU2009324371B2 (Direct)
BR (1) BRPI0922730A2 (Direct)
CA (1) CA2745938C (Direct)
CL (1) CL2011001406A1 (Direct)
CO (1) CO6361952A2 (Direct)
CY (2) CY1117735T1 (Direct)
DK (2) DK3072906T3 (Direct)
EC (1) ECSP11011192A (Direct)
ES (2) ES2579835T3 (Direct)
HR (2) HRP20160754T1 (Direct)
HU (2) HUE028408T2 (Direct)
IL (3) IL264316B2 (Direct)
LT (1) LT3072906T (Direct)
MA (1) MA33023B1 (Direct)
MX (1) MX2011006242A (Direct)
MY (2) MY157772A (Direct)
NZ (1) NZ592918A (Direct)
PE (1) PE20120342A1 (Direct)
PL (2) PL2376533T3 (Direct)
PT (2) PT2376533T (Direct)
RU (2) RU2563179C2 (Direct)
SI (2) SI2376533T1 (Direct)
SM (1) SMT201600222B (Direct)
TN (1) TN2011000229A1 (Direct)
WO (1) WO2010066762A1 (Direct)
ZA (1) ZA201103362B (Direct)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
AU2011219715B2 (en) 2010-02-26 2014-12-11 Novo Nordisk A/S Stable antibody containing compositions
ES2765418T3 (es) 2010-03-01 2020-06-09 Bayer Healthcare Llc Anticuerpos monoclonales optimizados contra el inhibidor de la ruta del factor tisular (TFPI)
JP6294075B2 (ja) 2010-05-28 2018-03-14 ノヴォ ノルディスク アー／エス 抗体及び防腐剤を含む安定した多用量組成物
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN103282042B (zh) 2010-09-17 2014-12-10 巴克斯特国际公司 通过具有组氨酸的水性制剂在弱酸性至中性pH稳定的免疫球蛋白
MX2013003681A (es) 2010-10-01 2013-11-20 Moderna Therapeutics Inc Ácidos nucleicos manipulados y métodos de uso de los mismos.
JP2014510730A (ja) 2011-03-16 2014-05-01 サノフイ デュアルｖ領域抗体様タンパク質の使用
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SI3682905T1 (sl) 2011-10-03 2022-04-29 Modernatx, Inc. Modificirani nukleozidi, nukleotidi in nukleinske kisline ter njihove uporabe
FI123630B (fi) 2011-10-24 2013-08-30 Teknologian Tutkimuskeskus Vtt Menetelmä NFC-kalvojen valmistamiseksi alustoille
WO2013082282A1 (en) 2011-12-02 2013-06-06 lNOVARTIS AG Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease.
US20130156849A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
CA2864539C (en) * 2012-02-16 2022-06-07 Santarus, Inc. Antibody formulations
DK2825037T3 (da) * 2012-03-16 2019-07-29 Regeneron Pharma Gnavere, der udtrykker pH-sensitive immunoglobulinsekvenser
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
HK1206601A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
KR20240091288A (ko) * 2012-09-20 2024-06-21 모르포시스 아게 류마티스 관절염에 대한 치료
JP2016502526A (ja) * 2012-11-16 2016-01-28 ノバルティス アーゲー 末梢動脈疾患を処置するためのＩＬ−１β結合抗体の使用
SI2922554T1 (sl) 2012-11-26 2022-06-30 Modernatx, Inc. Terminalno modificirana RNA
US20160002342A1 (en) * 2013-03-15 2016-01-07 Xinghang Ma Anti-prolactin receptor antibody formulations
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
WO2015181757A1 (en) * 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
JP2017527560A (ja) * 2014-09-03 2017-09-21 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 安定抗ｉｌ−４ｒアルファ抗体配合物
US10155820B2 (en) 2014-11-12 2018-12-18 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
US11058769B2 (en) 2015-12-07 2021-07-13 Merck Patent Gmbh Aqueous pharmaceutical formulation comprising anti-PD-L1 antibody Avelumab
EP3909985A1 (en) * 2016-06-27 2021-11-17 MorphoSys AG Anti-cd19 antibody formulations
KR20190032436A (ko) * 2016-07-21 2019-03-27 노파르티스 아게 폐 유육종증의 증상을 치료하거나 완화하기 위한 il-1beta 결합 항체 카나키누맙의 용도
KR102546471B1 (ko) * 2016-09-27 2023-06-21 프레제니우스 카비 도이치란트 게엠베하 액상의 약학 조성물
RU2767793C2 (ru) 2016-11-18 2022-03-21 Астеллас Фарма Инк. НОВЫЙ Fab-ФРАГМЕНТ АНТИТЕЛА ПРОТИВ MUC1 ЧЕЛОВЕКА
JP2020524694A (ja) * 2017-06-22 2020-08-20 ノバルティス アーゲー がんの処置における使用のためのＩＬ−１β結合性抗体
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
CA3075711A1 (en) * 2017-09-13 2019-03-21 Novartis Ag Use of il-1 b binding antibodies for the treatment of alcoholic hepatitis
AU2019237252A1 (en) * 2018-03-23 2020-10-22 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
MX2020012351A (es) 2018-05-17 2021-01-29 Astellas Pharma Inc Complejo que tiene fragmento fab de anticuerpo anti-muc1 de humano, enlazador peptido y/o ligando.
SG11202103670XA (en) 2018-10-10 2021-05-28 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
US11634485B2 (en) * 2019-02-18 2023-04-25 Eli Lilly And Company Therapeutic antibody formulation
CN113967195A (zh) * 2020-07-22 2022-01-25 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体冻干制剂及其制备方法
EP4268803A4 (en) * 2020-12-22 2025-04-16 Bio-Thera Solutions, Ltd. Stable antibody preparation, preparation method for same, and applications thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
CN102416176A (zh) 1995-07-27 2012-04-18 基因技术股份有限公司 稳定等渗的冻干蛋白质制剂
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
CA2411374C (en) 2000-06-29 2012-10-30 Abbott Laboratories Dual specificity antibodies and methods of making and using
WO2002011753A1 (en) * 2000-08-04 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
NZ532896A (en) * 2001-11-08 2007-08-31 Pdl Biopharma Inc Stable liquid pharmaceutical formulation of IGG antibodies including daclizumab and fontolizumab
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
SI2335725T1 (sl) * 2003-04-04 2017-01-31 Genentech, Inc. Visokokoncentrirane formulacije protiteles in proteinov
CN101111264A (zh) * 2005-01-28 2008-01-23 惠氏公司 稳定化的液体多肽制剂
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
NZ561137A (en) * 2005-03-08 2011-09-30 Pharmacia & Upjohn Co Llc Stable anti-CTLA-4 antibody compositions with chelating agents
WO2006125207A2 (en) * 2005-05-19 2006-11-23 Amgen Inc. Compositions and methods for increasing the stability of antibodies
JP2009513645A (ja) 2005-10-26 2009-04-02 ノバルティス アクチエンゲゼルシャフト ＩＬ−１β化合物の新規使用
CN201044845Y (zh) * 2006-10-28 2008-04-09 李开元 自动注射器
MX2009006199A (es) * 2006-12-11 2009-06-22 Hoffmann La Roche Formulacion parenteral de anticuerpos abeta.
EA200970880A1 (ru) * 2007-03-22 2010-02-26 Имклоун Элэлси Стабильные композиции на основе антител
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery

Also Published As

Publication number Publication date
PL3072906T3 (pl) 2022-01-24
JP7286595B2 (ja) 2023-06-05
ES2579835T3 (es) 2016-08-17
CN104399076A (zh) 2015-03-11
CA2745938A1 (en) 2010-06-17
SI3072906T1 (sl) 2022-01-31
IL212922A0 (en) 2011-07-31
JP2020203889A (ja) 2020-12-24
EP3792282A1 (en) 2021-03-17
KR20170044211A (ko) 2017-04-24
HRP20211899T1 (hr) 2022-03-04
IL264316B2 (en) 2024-01-01
EP2376533A1 (en) 2011-10-19
PT3072906T (pt) 2021-12-14
RU2015132431A (ru) 2018-12-24
AU2009324371A1 (en) 2011-06-23
EP2196476A1 (en) 2010-06-16
SI2376533T1 (sl) 2016-07-29
KR20120009421A (ko) 2012-01-31
US20120315285A1 (en) 2012-12-13
CO6361952A2 (es) 2012-01-20
ECSP11011192A (es) 2011-08-31
CA2745938C (en) 2018-04-24
ES2900624T3 (es) 2022-03-17
BRPI0922730A2 (pt) 2018-11-06
US20110236398A1 (en) 2011-09-29
CY1117735T1 (el) 2017-05-17
MX2011006242A (es) 2011-06-24
DK2376533T3 (en) 2016-06-27
US20200384108A1 (en) 2020-12-10
MY166050A (en) 2018-05-22
RU2011127913A (ru) 2013-01-20
RU2563179C2 (ru) 2015-09-20
EP3072906A1 (en) 2016-09-28
JP2023109938A (ja) 2023-08-08
JP2012511540A (ja) 2012-05-24
DK3072906T3 (da) 2021-12-13
MA33023B1 (fr) 2012-02-01
TN2011000229A1 (en) 2012-12-17
HK1159130A1 (zh) 2012-07-27
HUE056626T2 (hu) 2022-02-28
EP3072906B1 (en) 2021-09-08
HRP20160754T1 (hr) 2016-08-12
PT2376533T (pt) 2016-07-13
SMT201600222B (it) 2016-08-31
IL264316B1 (en) 2023-09-01
JP2015231997A (ja) 2015-12-24
CL2011001406A1 (es) 2012-03-30
CY1124844T1 (el) 2022-11-25
IL212922B (en) 2019-02-28
WO2010066762A1 (en) 2010-06-17
US8623367B2 (en) 2014-01-07
HUE028408T2 (en) 2016-12-28
RU2745601C2 (ru) 2021-03-29
IL276622A (en) 2020-09-30
LT3072906T (lt) 2021-12-27
MY157772A (en) 2016-07-29
NZ592918A (en) 2012-12-21
RU2015132431A3 (Direct) 2018-12-24
JP2018168158A (ja) 2018-11-01
CN102245639B (zh) 2014-12-24
PE20120342A1 (es) 2012-04-24
CN104399076B (zh) 2021-09-14
AU2009324371B2 (en) 2013-10-10
IL264316A (en) 2019-02-28
KR101762966B1 (ko) 2017-07-31
CN114225022A (zh) 2022-03-25
ZA201103362B (en) 2012-01-25
EP2376533B1 (en) 2016-03-30
JP6143416B2 (ja) 2017-06-07
CN102245639A (zh) 2011-11-16

Similar Documents

Publication Publication Date Title
IL276622A (en) Antibody formulation
HRP20181868T1 (hr) Anti-cmet antitijelo
EP2077859A4 (en) ANTIBODY FORMULATION
ZA201003907B (en) Antibody formulation
SG2014011365A (en) Novel antibody formulation
ZA201204266B (en) Antibody formulation
ZA201106503B (en) Antibody formulation
ZA201203242B (en) Antibody formulation
ZA201102119B (en) Improved antibody libraies
GB0822633D0 (en) Formulation
ZA201004772B (en) Novel formulation
GB0814376D0 (en) Formulation
GB0911770D0 (en) Antibody
GB0817622D0 (en) Antibody
GB0817621D0 (en) Antibody
HK1162914A (en) Antibody formulation
GB0817663D0 (en) Formulation
GB0806445D0 (en) Formulation
GB0819113D0 (en) An antibody
HK1166087A (en) Antibody formulation